Saw palmetto hair loss treatments have gained popularity as a natural alternative to conventional therapies, but how well does the evidence stack up? Saw palmetto (Serenoa repens) is a herbal supplement traditionally used for prostate and urinary conditions, now increasingly explored for androgenetic alopecia — the most common cause of hair thinning in men and women. It is thought to work by inhibiting the enzyme 5-alpha reductase, thereby reducing levels of DHT, the hormone that miniaturises hair follicles. This article examines the science, safety, and UK regulatory context to help you make an informed decision.

How Saw Palmetto May Affect Hair Loss

Saw palmetto is thought to inhibit 5-alpha reductase, reducing DHT and slowing follicle miniaturisation, but this mechanism is based largely on preclinical data and its clinical potency is markedly lower than finasteride.

Saw palmetto (Serenoa repens) is a small palm plant native to North America, traditionally used in herbal medicine for urinary and prostate conditions. In recent years, it has attracted growing interest as a potential natural remedy for hair loss, particularly androgenetic alopecia — the most common form of hair thinning in both men and women.

The proposed mechanism centres on the inhibition of 5-alpha reductase, an enzyme responsible for converting testosterone into dihydrotestosterone (DHT). DHT is widely recognised as a key driver of androgenetic alopecia, as it binds to receptors in hair follicles and progressively miniaturises them, leading to thinner, shorter hairs and eventual follicle dormancy. By reducing DHT activity, saw palmetto is thought to slow or partially reverse this process. It is important to note, however, that this mechanism is based largely on preclinical (in vitro and animal) data; robust clinical evidence in humans remains limited, and the degree of enzyme inhibition varies considerably between individuals and preparations.

This mechanism is pharmacologically similar — though markedly less potent clinically — to that of finasteride, a licensed 5-alpha reductase inhibitor used medically for hair loss. Saw palmetto is believed to act on both type I and type II isoforms of the enzyme, though the clinical relevance of this activity has not been established with certainty.

Regarding regulatory status, most saw palmetto products sold in the UK are marketed as food supplements and are not subject to the same rigorous quality controls as licensed medicines. Some products hold a Traditional Herbal Registration (THR) granted by the Medicines and Healthcare products Regulatory Agency (MHRA), but THR authorisations cover only traditional indications — specifically urinary symptoms associated with benign prostatic hyperplasia — and do not extend to hair loss. Saw palmetto has not been formally evaluated by the MHRA or the European Medicines Agency (EMA) for use in hair loss, and its efficacy for this purpose has not been established through the regulatory process. The EMA's Committee on Herbal Medicinal Products (HMPC) has published a community herbal monograph for Serenoa repens that reflects this position.

What the Evidence Says About Saw Palmetto for Hair

Clinical evidence for saw palmetto in hair loss is limited and of low to very low certainty; small trials show modest benefit, but NICE and major UK dermatology bodies do not recommend it.

The clinical evidence base for saw palmetto in hair loss remains limited and heterogeneous. Several small-scale studies and randomised controlled trials have produced modestly encouraging results, but the overall certainty of evidence is low to very low, and no definitive conclusions can be drawn.

A frequently cited study published in the Journal of Alternative and Complementary Medicine (Prager et al., 2002) found that oral saw palmetto extract led to increased hair count in a proportion of men with mild-to-moderate androgenetic alopecia over 21 weeks. A later randomised controlled trial (Rossi et al., 2012) compared saw palmetto (320 mg daily) with finasteride (1 mg daily) over 24 months and found that finasteride produced superior outcomes in hair density, though saw palmetto demonstrated some improvement compared to baseline. These trials involved small numbers of participants, and their findings should be interpreted with caution given the limited sample sizes, short follow-up periods, and variability in product formulations and outcome measures. A more recent systematic review and meta-analysis (Evron et al., 2020) similarly concluded that while some benefit was observed, the overall evidence base is insufficient to support routine clinical use.

For women, evidence is even more sparse. Androgenetic alopecia in women involves a more complex hormonal profile, and the role of DHT inhibition is less straightforward. Any consideration of saw palmetto in women should be clinician-guided and only after evaluation for reversible underlying causes such as polycystic ovary syndrome (PCOS), thyroid dysfunction, or iron deficiency.

Key limitations across the existing research include:

• Small sample sizes and short follow-up periods

• Inconsistent dosing and varying product formulations

• Lack of standardisation in outcome measures

• Overall low to very low certainty of evidence

NICE does not currently recommend saw palmetto for hair loss, and no major UK clinical guideline — including those from the Primary Care Dermatology Society (PCDS) or the British Association of Dermatologists (BAD) — endorses its use for this purpose. Patients should approach claims with appropriate caution and discuss options with a qualified healthcare professional before starting supplementation.

How to Use Saw Palmetto Safely in the UK

Choose a product standardised to 85–95% fatty acids and sterols, take 320 mg daily with food, and consult your GP or pharmacist first — especially if you take other medicines or have underlying health conditions.

If you are considering saw palmetto for hair loss, it is essential to approach its use thoughtfully and with appropriate professional guidance. As most products are sold as food supplements rather than licensed medicines in the UK, they are not subject to the same rigorous quality controls as pharmaceutical drugs. This means potency, purity, and bioavailability can vary considerably between brands.

When selecting a product, look for supplements that:

• Are standardised to contain 85–95% fatty acids and sterols (liposterolic extract), which are considered the pharmacologically active constituents in most studied preparations

• Are manufactured by reputable companies adhering to Good Manufacturing Practice (GMP) standards

• Are clearly labelled with the extract type, standardisation level, and batch information

Note that while some saw palmetto products carry an MHRA Traditional Herbal Registration (THR) mark, this signifies quality and safety standards for the approved traditional indication (urinary symptoms) only — it does not indicate that the product is authorised or evidenced for hair loss. The THR mark should not be interpreted as regulatory endorsement for use in alopecia.

The most commonly studied oral dose in clinical trials is 320 mg per day of a standardised liposterolic extract, typically taken as a single dose or split into two doses with food to reduce gastrointestinal discomfort. Topical formulations are also available and may carry a lower risk of systemic side effects, though evidence for topical use is even more limited than for oral preparations.

Additional precautions to be aware of:

• Saw palmetto is not recommended for use in under-18s, as safety data in this age group are absent.

• If you are due to undergo surgery, consider stopping saw palmetto at least two weeks beforehand, owing to a potential increased risk of bleeding.

• If you have liver disease or are taking anticoagulant or antiplatelet medicines, consult your GP or pharmacist before use.

It is advisable to inform your GP or pharmacist before starting saw palmetto, particularly if you are taking other medications or have underlying health conditions. Saw palmetto should not be viewed as a replacement for evidence-based treatments. Results, if any, are likely to be gradual — most studies suggest a minimum of three to six months of consistent use before any meaningful change in hair density may be observed, and this timeframe is extrapolated largely from studies in benign prostatic hyperplasia rather than hair loss specifically.

Possible Side Effects and Risks to Be Aware Of

Common side effects include gastrointestinal upset and headache; rare but serious risks include liver injury and increased bleeding, and the supplement must be avoided entirely in pregnancy.

Saw palmetto is generally considered well tolerated when taken at recommended doses, and serious adverse effects are uncommon. However, as with any supplement, there are potential risks that users should be aware of before starting.

The most frequently reported side effects include:

• Gastrointestinal symptoms — nausea, stomach discomfort, diarrhoea, or constipation, particularly when taken on an empty stomach

• Headache and dizziness, reported in a minority of users

• Reduced libido or changes in sexual function, though these appear to be reported less frequently than with pharmaceutical 5-alpha reductase inhibitors such as finasteride

There are also important safety considerations for specific groups:

• Pregnancy and breastfeeding: Saw palmetto should be avoided entirely. There are insufficient safety data, and its potential hormonal activity raises theoretical concerns regarding foetal development. There is no established safe dose in pregnancy or during breastfeeding.

• Hormone-sensitive conditions: Individuals with conditions such as breast cancer, uterine fibroids, or endometriosis should seek medical advice before use, given the supplement's potential influence on androgen pathways.

• Anticoagulant and antiplatelet medicines: Saw palmetto may increase bleeding risk when taken alongside medicines such as warfarin, aspirin, or clopidogrel. If you take any of these, consult your GP or pharmacist before use. This risk is also relevant if you are planning surgery (see above).

• Hormonal therapies: If you are using hormonal contraceptives or hormone replacement therapy (HRT), discuss with your clinician before starting saw palmetto, as the potential for interaction has not been well characterised and the evidence is limited.

Rare but important risks to be aware of include:

• Liver injury (hepatotoxicity): There are case reports of liver injury associated with saw palmetto use. If you develop jaundice (yellowing of the skin or whites of the eyes), dark urine, pale stools, or persistent upper abdominal pain, stop taking saw palmetto immediately and seek urgent medical attention.

• Severe allergic reactions: Although uncommon, reactions including skin rash, itching, facial swelling, or swelling of the lips or tongue have been reported. If you experience any of these, stop use and seek prompt medical advice.

If you experience any suspected adverse reaction to saw palmetto or any other supplement, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. This reporting helps the MHRA monitor the safety of herbal products in the UK.

Regulated Treatments Available for Hair Loss on the NHS

Minoxidil (over the counter) and finasteride (prescription-only for men) are the principal evidence-based, regulated treatments for androgenetic alopecia recognised by NICE and the NHS.

For those experiencing significant hair loss, it is worth exploring the range of clinically validated, regulated treatments available in the UK before or alongside considering supplements such as saw palmetto. NICE, the NHS, and the Primary Care Dermatology Society (PCDS) recognise several evidence-based options depending on the type and severity of hair loss.

Minoxidil (available over the counter as a 2% or 5% solution or foam, under various brand names) is a topical treatment licensed for androgenetic alopecia in both men and women. Its precise mechanism is not fully understood, but it is thought to act via potassium channel opening and prolongation of the anagen (growth) phase of the hair cycle, with improved follicular blood supply also proposed. It requires consistent, long-term use to maintain results, and hair loss typically resumes if treatment is stopped.

Finasteride (1 mg daily, oral) is a prescription-only 5-alpha reductase inhibitor licensed for male androgenetic alopecia. It is not licensed for use in women of childbearing potential due to teratogenic risk. Finasteride has a substantially stronger and more consistent evidence base than saw palmetto and is considered a first-line pharmacological option for eligible men. Full prescribing information is available via the electronic Medicines Compendium (eMC) at medicines.org.uk.

For other forms of alopecia, such as alopecia areata, treatments may include topical or intralesional corticosteroids, topical immunotherapy, or referral to a dermatologist. The NHS also provides access to wigs and hairpieces for patients with certain conditions causing significant hair loss.

When to seek medical advice promptly

You should consult your GP if hair loss is:

• Sudden in onset or progressing rapidly

• Patchy, or associated with scalp changes such as redness, scaling, pustules, or pain (which may suggest scarring alopecia or tinea capitis, particularly in children with associated lymphadenopathy)

• Accompanied by loss of eyebrows or eyelashes

• Associated with systemic symptoms such as fatigue, weight change, or menstrual irregularity

Before attributing hair loss to androgenetic alopecia or pursuing any treatment, your GP may arrange basic investigations to exclude reversible causes. These typically include a full blood count (FBC), serum ferritin, and thyroid-stimulating hormone (TSH). In women with signs of hyperandrogenism (such as acne, hirsutism, or irregular periods), assessment of total and free testosterone and sex hormone-binding globulin (SHBG) may also be appropriate, alongside evaluation for PCOS.

For further information, the NHS Hair Loss patient page, NICE Clinical Knowledge Summaries, PCDS guidance, and British Association of Dermatologists (BAD) patient information leaflets provide reliable, up-to-date resources.

Frequently Asked Questions